original ) (raw )Value of intravenous 6-mercaptopurine during continuation treatment in childhood acute lymphoblastic leukemia and non-Hodgkin's lymphoma: final results of a …
J. Otten
Leukemia, 2005
View PDFchevron_right
Intraindividual variation in 6-mercaptopurine pharmacokinetics during oral maintenance therapy of children with acute lymphoblastic leukaemia
Pierre Lafolie
European journal of clinical pharmacology, 1991
View PDFchevron_right
6-Mercaptopurine in cerebrospinal fluid during oral maintenance therapy of children with acute lymphoblastic leukemia
Pierre Lafolie
Medical oncology and tumor pharmacotherapy, 1988
View PDFchevron_right
Pharmacokinetic determinants of 6-mercaptopurine myelotoxicity and therapeutic failure in children with acute lymphoblastic leukemia
Mark Greenberg
Journal of Pediatric Health Care, 1987
View PDFchevron_right
Variability of 6-mercaptopurine pharmacokinetics during oral maintenance therapy of children with acute leukemia
Pierre Lafolie
Medical oncology and tumor pharmacotherapy, 1989
View PDFchevron_right
Intrathecal 6-mercaptopurine: preclinical pharmacology, phase I/II trial, and pharmacokinetic study
Prem Narang
Cancer research, 1991
View PDFchevron_right
Disposition of oral methotrexate in children with acute lymphoblastic leukemia and its relation to 6-mercaptopurine pharmacokinetics
Mark Greenberg
Medical and Pediatric Oncology, 2006
View PDFchevron_right
Symptomatic hypoglycemia in children receiving oral purine analogues for treatment of childhood acute lymphoblastic leukemia
Delia Russo
Medical and Pediatric Oncology, 2002
View PDFchevron_right
Maintenance therapy of childhood acute lymphoblastic leukemia revisited-Should drug doses be adjusted by white blood cell, neutrophil, or lymphocyte counts?
Richard Weinshilboum
Pediatric blood & cancer, 2016
View PDFchevron_right
Pharmacokinetics of high-dose methotrexate in infants treated for acute lymphoblastic leukemia
myriam campbell
Pediatric Blood & Cancer, 2009
View PDFchevron_right
Adherence to 6-Mercaptopurine in children and adolescents with Acute Lymphoblastic Leukemia
Rawad S Rihani
PLOS ONE
View PDFchevron_right
Oral 6-mercaptopurine versus oral 6-thioguanine and veno-occlusive disease in children with standard-risk acute lymphoblastic leukemia: report of the Children's Oncology Group CCG-1952 clinical trial
Archie Bleyer
Blood, 2010
View PDFchevron_right
Hematotoxicity in acute lymphoblastic leukemia children who received 6-Mercaptopurine during maintenance therapy in Indonesia
Dewi Selvina Rosdiana
Journal of International Dental and Medical Research, 2019
View PDFchevron_right
Systemic effect of intrathecal methotrexate during the initial phase of treatment of childhood acute lymphoblastic leukemia. The European Organization for Research and Treatment of Cancer Children's Leukemia Cooperative Group
Hisham Saad
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1997
View PDFchevron_right
Populationpharmacokinetic and pharmacogenetic analysis of 6-mercaptopurine in paediatric patients with acute lymphoblastic leukaemia
Ahmed Hawwa
British Journal of Clinical Pharmacology, 2008
View PDFchevron_right
Benefits of the Intermittent Use of 6-Mercaptopurine and Methotrexate in Maintenance Treatment for Low-Risk Acute Lymphoblastic Leukemia in Children: Randomized Trial From the Brazilian Childhood Cooperative Group—Protocol ALL-99
MARCOS ROCHA VIANA
Journal of Clinical Oncology, 2010
View PDFchevron_right
Cranial irradiation and cerebrospinal fluid levels of 6-mercaptopurine in children with acute leukemia
Riccardo Riccardi
Medical oncology and tumor pharmacotherapy, 1991
View PDFchevron_right
Intensification of Mercaptopurine/Methotrexate Maintenance Chemotherapy May Increase the Risk of Relapse for Some Children With Acute Lymphoblastic Leukemia
Richard Weinshilboum
Journal of Clinical Oncology, 2003
View PDFchevron_right
HPLC Determination of the Levels of 6-Mercaptopurine Metabolites Suitable for the Clinical Risk Assessment of its Toxicity among Egyptian Children with Acute Lymphocytic Leukemia
Iman Sidhom
Journal of Analytical & Bioanalytical Techniques, 2017
View PDFchevron_right
Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia
Richard Weinshilboum
The Lancet, 1990
View PDFchevron_right
Personalized Treatment of 6-Mercaptopurine in Thai Children with Acute Lymphoblastic Leukemia
Trai Tharnpanich
2021
View PDFchevron_right
Randomized assessment of delayed intensification and two methods for parenteral methotrexate delivery in childhood B-ALL: Children’s Oncology Group Studies P9904 and P9905
Naomi Winick
Leukemia
View PDFchevron_right
Association of delivered drug dose and outcome for children with acute lymphoblastic leukemia and unfavorable presenting features
Archie Bleyer
Medical and Pediatric Oncology, 1991
View PDFchevron_right
The role of pharmacokinetic and pharmacodynamic studies in the planning of protocols for the treatment of childhood cancer
Stephen Lowis
Cancer Treatment Reviews, 1999
View PDFchevron_right
Antimetabolite therapy for lesser-risk B-lineage acute lymphoblastic leukemia of childhood: a report from Children's Oncology Group Study P9201
Meenakshi Devidas
Blood, 2007
View PDFchevron_right
Pharmacokinetics of continuous infusion of methotrexate and teniposide in pediatric cancer patients
Marc Sunderland
Cancer research, 1990
View PDFchevron_right
Acute lymphoblastic leukemia and down syndrome: 6-mercaptopurine and methotrexate metabolites during maintenance therapy
Matilda Degn Vinther
Leukemia, 2020
View PDFchevron_right